Clinical Trial Update: A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib in combination with CHEP for peripheral T cell lymphoma is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CHEP

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: UNKNOWN